XT
BTAI icon

XTX Topco’s BioXcel Therapeutics BTAI Stock Holding History

XTX Topco’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-113,364
Closed -$290K – 3348
2025
Q3 		$290K Buy
113,364
+89,940
+384% +$284K 0.02% 1534
2025
Q2 		$42.4K Buy
+23,424
New +$38.8K ﹤0.01% 2045
2024
Q4 		– Sell
-669
Closed -$6.53K – 2327
2024
Q3 		$6.53K Sell
669
-2,237
-77% -$30.1K ﹤0.01% 1962
2024
Q2 		$59.5K Buy
2,906
+955
+49% +$32K 0.01% 1490
2024
Q1 		$88K Buy
+1,951
New +$93.1K 0.01% 1389
2023
Q4 		– Sell
-2,100
Closed -$85K – 1627
2023
Q3 		$85K Buy
2,100
+1,068
+103% +$108K 0.01% 1206
2023
Q2 		$110K Buy
+1,032
New +$344K 0.02% 1153

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco's BTAI Position: Q4 2025 in Review

XTX Topco sold out of BioXcel Therapeutics (BTAI) in Q4 2025, closing a stake of 113,364 shares — an estimated $290K sold.

XTX Topco first reported a position in BTAI in Q2 2023 and held it in 7 quarters. The position peaked at $290K in Q3 2025. 41 funds tracked by Wall St. Rank hold BTAI as of Q4 2025.

  • XTX Topco reported no remaining BioXcel Therapeutics position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 113,364 BioXcel Therapeutics shares in Q4 2025, an estimated $290K.
  • XTX Topco first reported a position in BioXcel Therapeutics in Q2 2023 and held it in 7 quarters.
  • XTX Topco's BioXcel Therapeutics position peaked at $290K in Q3 2025.
  • 41 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.